BREAST CANCER

Christiane K. Kuhl, MD, Department of Diagnostic and Interventional Radiology, RWTH University of Aachen, discusses an observational cohort study looking at breast MRI screening of women at average risk of breast cancer.

The treatment of TNBC continues to be a challenge for physicians because of its limited treatment options, the dearth of approved targeted therapies, high mortality, and poor prognosis.

While TNBC is a heterogeneous group of breast cancers there is increasing effort to subdivide it into more homogenous groups that may help in more accurate prognosis and response to therapy.

Breast cancer is a leading cause of cancer death in women, with 12% to 20% of cases classified as triple-negative breast cancer (TNBC).

Oncoviruses have been implicated to cause 17.8% of human cancers.

The bovine leukemia virus, or BLV, which is transmitted between cattle herds may play a key role in the development of breast cancer.

Lajos Pusztai, MD, PhD, Yale Cancer Center, discusses DNA abnormalities in breast cancer.

Anees B. Chagpar, MD, MPH, MBA, Yale Comprehensive Cancer Center, discusses contralateral prophylactic mastectomy for patients with breast cancer.

Jeffrey N. Weitzel, MD, director, Clinical Cancer Genetics, director, Cancer Screening & Prevention Program Network, professor, City of Hope, discusses the impact of gene mutations on treatment.

Fred C. Kass, MD, oncology/hematology, internal medicine, Cancer Center of Santa Barbara, discusses HER2-positive breast cancer advancements.

Melvin J. Silverstein, MD, FACS, Hoag Memorial Hospital Presbyterian, discusses the benefits of oncoplastic surgery for patients with breast cancer.

Anthony D. Elias, MD, professor, Division of Medical Oncology, University of Colorado Denver, discusses the future of androgen receptors in breast cancer.

Erika P. Hamilton, MD, associate director, Breast Cancer and Gynecologic Cancer Research Program, principal investigator, Sarah Cannon Research Institute, discusses the challenges associated with utilizing new agents in HER2-positive breast cancer.

Young black women have a higher prevalence of BRCA mutations compared with that previously reported among non-Hispanic white women.

Sara M. Tolaney, MD, MPH, physician, instructor in medicine, Harvard Medical School, medical oncologist, Dana-Farber Cancer Institute, discusses patient selection for platinum-based therapy in triple-negative breast cancer (TNBC).

Early detection of metastasis in patients with breast cancer, which is critical for designing effective targeted therapies, has unfortunate limitations with prevalent screening methods. A study published in Nature Communications has shown promise for extending the detection limit of the current clinical imaging technology

A publication in Scientific Reports has identified a novel biomarker, diaphanous-related formin-3 (DIAPH3), which may help predict response to taxane-based chemotherapies in patients with metastatic breast or prostate cancer.

Evidence is mounting for multigene panel testing in women with suspected familial breast and/or ovarian cancer.

Almost 10 years following a study that proved intraperitoneal (IP), or abdominal, chemotherapy, along with intravenous (IV) therapy, may add 16 months or more to the lives of women with ovarian cancer, less than half of these patients at US hospitals receive this type of treatment

Rita Nanda, MD, assistant professor of Medicine, associate director, Breast Medical Oncology, The University of Chicago Medicine, discusses the treatment of metastatic triple-negative breast cancer (TNBC).

Rowan T. Chlebowski, MD, PhD, professor and chief, Harbor-University of California Los Angeles Medical Center, Department of Internal Medicine, Medical Oncology/Hematology, discusses breast cancer prevention.

While targeting HER2 mutations is mainly associated with breast cancer, there could be therapeutic potential with anti-HER2 agents in non-small cell lung cancer (NSCLC).

Douglas Yee, MD, professor of medicine and pharmacology, Hematology, Oncology and Transplantation, Department of Medicine, medical oncologist, University of Minnesota, discusses the results of the phase II ADAPT trial.

Pertuzumab (Perjeta), in combination with trastuzumab (Herceptin) and chemotherapy, was approved by the European Commission (EC) as a neoadjuvant therapy for adult patients who have HER2-positive, locally advanced, inflammatory, or early stage breast cancer and are at high risk of recurrence.

Major disparities in compliance, follow-up, and access have been identified in the Appalachian region of the United States, according to researchers from the University of Virginia School of Medicine.